TRAUMAGEL: The Plant-Based Gel That Stops Bleeding in Seconds

Every year, 1.75 million people die from uncontrolled bleeding — not from their injuries, but from blood that couldn't be stopped in time (WHO, 2024). Hemorrhage causes over 80% of operating-room deaths following major trauma, and on the battlefield, 91% of potentially survivable combat deaths trace back to the same cause (Kauvar et al., Journal of Trauma, 2006; Eastridge et al., Journal of Trauma and Acute Care Surgery, 2012).

Cresilon, a Brooklyn-based biotechnology company, built a direct answer to that problem. Their plant-based hemostatic gel, TRAUMAGEL, received FDA 510(k) clearance in August 2024, launched nationwide in January 2025, and in 2026 earned Cresilon the #1 spot in Fast Company's Most Innovative Medical Device Companies — #46 across every industry on earth.

What Is TRAUMAGEL?

TRAUMAGEL is a flowable hemostatic gel made from plant-derived polysaccharide polymers — the same structural molecules found in plant cell walls. It comes in a sterile, single-use 30mL prefilled syringe, requires zero preparation, and is designed for immediate use at the point of injury.

When applied to a wound, the gel flows into the injury — filling irregular spaces, adapting to complex wound geometries — and forms an instant mechanical barrier that supports the body's natural clotting process. No heat. No electricity. No manual pressure needed. Bleeding slows, then stops, in seconds.

How It Works

Unlike gauze or tourniquets that rely on compression, TRAUMAGEL works through contact chemistry. The plant-derived polymers interact directly with blood, creating a physical seal that conforms to the wound's shape — whether it's a clean laceration, a deep puncture, a gunshot wound, or a partial amputation.

Three properties define it in the field:

FAST — no mixing, no activation, no warming. Open the syringe and apply.

EASY — usable by EMTs, paramedics, military medics, police officers, and firefighters without specialized surgical training.

RELIABLE — effective from point of injury through hospital transport and into the emergency room. A wound stabilized with TRAUMAGEL stays stabilized.

Who Can Use It and Where to Get It

TRAUMAGEL is commercially available now across the United States. It is cleared for use by EMTs, paramedics, first responders, emergency departments, trauma hospitals, military units, and law enforcement agencies. It is not a consumer product — procurement is through professional medical suppliers including Life-Assist and Pacific Biomedical, which ships nationwide within 24 hours.

In March 2026, Cresilon received an Innovative Technology contract from Vizient — the largest provider-driven healthcare performance improvement company in the US, representing over $156 billion in annual purchasing volume — further opening access across academic medical centers, community hospitals, and integrated health networks nationwide.

Real-World Proof

TRAUMAGEL isn't theoretical. In 2026, Cresilon presented two peer-reviewed case studies at the Special Operations Medical Association (SOMA) Scientific Assembly — one covering prehospital hemorrhage control in the field, another documenting a partial hand amputation with ulnar artery transection successfully treated before hospital arrival. A 2026 PubMed-indexed study followed TRAUMAGEL use across traumatic extremity injuries including tourniquet removal cases. A 2025 large animal randomized controlled trial confirmed high efficacy in severe hemorrhage scenarios.

Before entering human medicine, Cresilon spent five years validating the same technology in veterinary medicine through VETIGEL — which has now supported over 65,000 procedures worldwide. That clinical foundation built the evidence base that earned FDA clearance for human use.